Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2025-10-09 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
关于可转债转股结果暨股份变动的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the conversion results of convertible bonds ('微芯转债') issued by Shenzhen Microchip Biotechnology Co., Ltd. It details the amount of bonds converted into shares during a specific quarter and cumulatively, as well as the remaining unconverted bonds. It includes information about the bond issuance, conversion price adjustments, and share capital changes due to the bond conversions. The document is relatively short (1958 characters) and focuses on the update of convertible bond conversions and resulting share capital changes. This fits the category of a Capital/Financing Update (CAP), as it relates to changes in the company's capital structure due to convertible bond conversions. It is not a full financial report, audit, or earnings release, nor is it a regulatory filing or announcement of a report publication. Therefore, the appropriate classification is CAP with high confidence.
2025-10-09 Chinese
关于收到国家知识产权局《无效宣告请求审查决定书》的公告
Legal Proceedings Report Classification · 95% confidence The document is an official announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding the receipt of a decision from the National Intellectual Property Office of China declaring a patent invalid. It details the patent invalidation decision, the involved parties, the impact on the company, and legal recourse options. The document is a regulatory announcement about a legal proceeding related to intellectual property rights, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. It is not a report publication announcement since it contains substantive content about the legal decision. Therefore, the document fits best under the category of Legal Proceedings Report (LTR).
2025-09-25 Chinese
毕马威华振会计师事务所(特殊普通合伙)关于深圳微芯生物科技股份有限公司向特定对象发行股票申请文件的审核问询函回复的专项说明
Audit Report / Information Classification · 95% confidence The document is an extensive audit-related report issued by KPMG Huazhen LLP concerning Shenzhen Microchip Biotechnology Co., Ltd.'s application for a private placement of shares. It includes detailed financial data, investment project breakdowns, capital expenditure analysis, and comparisons with industry peers. The document references audit reports for fiscal years ending 2022, 2023, and 2024, and discusses the audit procedures and findings related to the company's financial statements. The content is focused on audit verification and explanations related to the issuance of shares and the associated financial disclosures. It is not a full annual report, earnings release, or management discussion but rather a standalone audit report or audit-related information. The length (15,000 characters) and detailed financial and audit content confirm it is not a brief announcement or certification. Therefore, the document fits the category of Audit Report / Information (AR). FY 2024
2025-09-24 Chinese
关于深圳微芯生物科技股份有限公司2024年度向特定对象发行A股股票申请文件的审核问询函的回复
Capital/Financing Update Classification · 95% confidence The document is a detailed response to an inquiry letter from the Shanghai Stock Exchange regarding Shenzhen Microchip Biotechnology Co., Ltd.'s application for a 2024 private placement of A shares. It includes extensive discussion on the company's fundraising project, clinical trials, market analysis, and financial projections related to the issuance of new shares. The document is lengthy (15,000 characters) and contains substantive content about the financing, use of proceeds, and business plans tied to the capital raise. This indicates it is not merely an announcement but a comprehensive filing related to capital raising activities. The presence of terms like "募集资金" (fundraising), "向特定对象发行股票" (private placement of shares), and detailed project and financial discussions confirm this is a Capital/Financing Update filing rather than a simple announcement or other report type.
2025-09-24 Chinese
关于2024年度向特定对象发行A股股票申请文件的审核问询函回复的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (634 characters) regarding the company's response to a review inquiry letter from the Shanghai Stock Exchange about a specific issuance of A shares to targeted investors. It references regulatory review and approval processes but does not contain financial statements or detailed financial data. It is an update on a capital raising process, specifically about the application and review for a share issuance. Given the content and length, this fits best under Capital/Financing Update (CAP) rather than a full report or regulatory filing. The document is not a report publication announcement or a certification but an update on financing activity.
2025-09-24 Chinese
毕马威华振会计师事务所关于深圳微芯生物科技股份有限公司前次募集资金使用情况报告的鉴证报告
Audit Report / Information Classification · 95% confidence The document is a detailed verification report by KPMG Huazhen LLP on the use of previously raised funds by Shenzhen Microchip Biotechnology Co., Ltd. It references compliance with the China Securities Regulatory Commission's guidelines (specifically the "Regulatory Rules Applicable Guidelines - Issuance No. 7"), and it includes detailed financial data on the raised funds, their usage, changes in investment projects, and cash management of idle funds. The document is titled as a "Verification Report on the Use of Previously Raised Funds" and includes auditor's opinions, responsibilities, and attachments with detailed tables of fund usage and investment project performance. This is a standalone audit-related report focusing on the use of raised capital and compliance with regulatory requirements, not a full annual or interim report, nor a simple announcement. It is not a certification letter or a brief announcement but a comprehensive audit verification report. Therefore, it fits the category of Audit Report / Information (AR). The document length (15,000 characters) and content depth support this classification with high confidence. H1 2025
2025-09-15 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.